KEROS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.86 USD | +6.77% |
|
-0.72% | +45.52% |
| Mar. 19 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
| Mar. 15 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,635 | 1,369 | 1,323 | 1,191 | 2,087 | - | - |
| Enterprise Value (EV) 1 | 1,635 | 1,369 | 1,323 | 860 | 1,783 | 1,964 | 1,958 |
| P/E ratio | -24.1 x | -23.2 x | -11.6 x | -7.65 x | -11.1 x | -10.7 x | -11.6 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 68.1 x | - | 7,889 x | 368 x | 93,919 x | 55.1 x |
| EV / Revenue | - | 68.1 x | - | 5,696 x | 314 x | 88,383 x | 51.6 x |
| EV / EBITDA | - | - | - | -5.09 x | -9.9 x | -9.08 x | -8.43 x |
| EV / FCF | -44 x | -21.7 x | -18.5 x | -6.77 x | -9.93 x | -10.7 x | -12.4 x |
| FCF Yield | -2.27% | -4.61% | -5.39% | -14.8% | -10.1% | -9.37% | -8.04% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 23,178 | 23,399 | 27,543 | 29,959 | 36,068 | - | - |
| Reference price 2 | 70.54 | 58.51 | 48.02 | 39.76 | 57.86 | 57.86 | 57.86 |
| Announcement Date | 3/25/21 | 3/9/22 | 3/3/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 10 | - | 20.1 | - | 0.151 | 5.67 | 0.0222 | 37.91 |
| EBITDA 1 | - | - | - | - | -169.1 | -180.1 | -216.2 | -232.1 |
| EBIT 1 | - | -46.66 | -56.37 | -114.8 | -169.9 | -188.1 | -207.4 | -203.6 |
| Operating Margin | - | - | -280.46% | - | -112,543.71% | -3,316.65% | -933,430.92% | -537.18% |
| Earnings before Tax (EBT) 1 | - | -45.53 | -56.73 | -104.7 | -153 | -178 | -193.9 | -190.3 |
| Net income 1 | - | -45.36 | -58.74 | -104.7 | -153 | -175 | -199.7 | -199.9 |
| Net margin | - | - | -292.26% | - | -101,319.21% | -3,086.02% | -898,696.98% | -527.38% |
| EPS 2 | -2.800 | -2.930 | -2.520 | -4.150 | -5.200 | -5.222 | -5.424 | -4.994 |
| Free Cash Flow 1 | - | -37.19 | -63.17 | -71.3 | -127 | -179.6 | -184.1 | -157.5 |
| FCF margin | - | - | -314.29% | - | -84,087.42% | -3,167.04% | -828,412.83% | -415.44% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 3/25/21 | 3/9/22 | 3/3/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 20 | - | - | - | - | - | - | 0.00001 | 0.143 | - | - | - | 6.278 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.2 | -4.866 | -24.13 | -30.73 | -27.98 | -31.96 | -38.87 | -41.34 | -43.28 | -46.46 | -46.63 | -47.83 | -48.83 | -44.22 | -45 |
| Operating Margin | - | -24.33% | - | - | - | - | - | - | -432,800,000% | -32,486.01% | - | - | - | -704.43% | - |
| Earnings before Tax (EBT) 1 | -20.34 | -4.941 | -24.19 | -27.27 | -23.51 | -29.72 | -35.8 | -37.5 | -39.44 | -40.24 | -44.05 | -44.78 | -46.21 | -42.82 | -41.6 |
| Net income 1 | -20.3 | -6.94 | -24.19 | -27.27 | -23.51 | -29.72 | -35.8 | -37.5 | -39.44 | -40.24 | -43.64 | -44.16 | -45.61 | -41.13 | -41.6 |
| Net margin | - | -34.7% | - | - | - | - | - | - | -394,400,000% | -28,141.96% | - | - | - | -655.09% | - |
| EPS 2 | -0.8700 | -0.3000 | -1.010 | -1.130 | -0.9200 | -1.090 | -1.260 | -1.270 | -1.330 | -1.340 | -1.327 | -1.318 | -1.351 | -1.231 | -1.170 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/9/22 | 5/5/22 | 8/4/22 | 11/3/22 | 3/3/23 | 5/4/23 | 8/7/23 | 11/6/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 331 | 304 | 123 | 129 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -37.2 | -63.2 | -71.3 | -127 | -180 | -184 | -157 |
| ROE (net income / shareholders' equity) | - | - | - | - | -50.2% | -43.5% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | - | - | - | - | -4.230 | -3.300 | -4.440 | - |
| Capex 1 | - | 0.29 | 1.02 | 1.24 | 2.46 | 1.63 | 2.56 | 3.56 |
| Capex / Sales | - | - | 5.09% | - | 1,631.79% | 28.68% | 11,535.78% | 9.4% |
| Announcement Date | 2/27/20 | 3/25/21 | 3/9/22 | 3/3/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
57.86
USD
Average target price
88.11
USD
Spread / Average Target
+52.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +45.52% | 2.09B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- KROS Stock
- Financials Keros Therapeutics, Inc.
